Preston C. Sprenkle, MD, presented “NCCN Guidelines for Early Detection of Prostate Cancer 2023” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Sprenkle, Preston C. “NCCN Guidelines for Early Detection of Prostate Cancer 2023.” September 21, 2023. Accessed Nov 2024. https://grandroundsinurology.com/nccn-guidelines-for-early-detection-of-prostate-cancer-2023/
NCCN Guidelines for Early Detection of Prostate Cancer 2023 – Summary
Preston C. Sprenkle, MD outlines the 2023 NCCN Guidelines for Early Detection of Prostate Cancer, emphasizing the importance of these guidelines in standardizing prostate cancer screening and improving patient outcomes. These guidelines aim to balance the benefits of early cancer detection with the risks of overdiagnosis and overtreatment.
The guidelines advocate for shared decision-making between physicians and patients, emphasizing the importance of informed discussions about the benefits and harms of prostate-specific antigen (PSA) testing. Dr. Sprenkle also underscores the role of multiparametric MRI (mpMRI), particularly for men with elevated PSA levels or abnormal digital rectal exams. He discusses the incorporation of novel biomarkers, such as the Prostate Health Index (PHI) and the 4Kscore, which provide additional information to guide biopsy decisions.
Dr. Sprenkle explains that identifying high-risk individuals allows for more personalized screening strategies and early intervention. The guidelines provide criteria for selecting patients for active surveillance and outline protocols for monitoring, including periodic PSA testing, mpMRI, and repeat biopsies.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Preston C. Sprenkle, MD, is an Associate Professor of Urology at Yale University School of Medicine in New Haven, Connecticut. He also serves as Director of the Urology Research Fellowship and Urologic Oncology Clinical Fellowship Program at Yale, and as Division Chief of Urology in the VA Connecticut Healthcare System. Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device, and he is also a pioneer in focal therapy. In his practice, Dr. Sprenkle believes in working with patients to come up with individualized treatment plans to minimize the impact of prostate cancer diagnosis and treatment on their health and quality of life. His research focuses on biomarkers for prostate and kidney cancer, including the biomarker NGAL for acute kidney injury in surgical patients.
